Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 7/20 | 0.39 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738629 | 0.96 | CTSK (0.41) | DRD2DRD3CHRNA7MAP3K12CTSK | |
| SCHEMBL13496621 | 0.95 | CTSK (0.43) | DRD2DRD3MAP3K12CTSKCTSS | |
| SCHEMBL16094779 | 0.93 | MAP3K12 (0.43) | DRD2DRD3MAP3K12HCRTR1HCRTR2 | |
| SCHEMBL3394052 | 0.85 | CHRNA1 (0.42) | DRD2DRD3MAP3K12USP30 | |
| SCHEMBL3389679 | 0.85 | CHRNA1 (0.42) | DRD2DRD3MAP3K12USP30 | |
| SCHEMBL27454689 | 0.82 | CLK4 (0.40) | MAP3K12USP30 | |
| SCHEMBL5559799 | 0.80 | CLK4 (0.50) | DRD2DRD3USP30 | |
| SCHEMBL3230699 | 0.79 | MAP3K12 (0.53) | MAP3K12CSF1RMAPK8MAPK9MAPK10 | |
| SCHEMBL5564307 | 0.76 | CLK4 (0.53) | USP30 | |
| SCHEMBL23974912 | 0.74 | HDAC8 (0.40) | CHRNA7MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773088-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773088-B2 | KCNT1 inhibitors and methods of use | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220135553-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167102-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | DRD2 2859/4885DRD3 3113/4885CHRNA7 142/4885 |
| US-11773088-B2 | KCNT1 inhibitors and methods of use | KCNT1, KCNT2, KCNQ2 | DRD2 2859/4885DRD3 3113/4885CHRNA7 142/4885 |
| US-20220135553-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | DRD2 2859/4885DRD3 3113/4885CHRNA7 142/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | DRD2 2859/4885DRD3 3113/4885CHRNA7 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.